Effect of Dexmedetomidine reducing the brain injury during cardiopulmonary bypass coronary artery bypass grafting

Objective To observe the changes of Dexmedetomidine influencing neuron-specific enolase(NSE), S-100 B protein level and indexes of cerebral oxygen metabolism during cardiopulmonary bypass(CPB) coronary artery bypass grafting(CABG), and explore the protection on the operation of patients with brain injury. Methods 80 patients in the Second Xiangya Hospital of Changsha City for elective CPB downlink CABG were chosen, then they were divided into experimental group and control group. The experimental group was given Dexmedetomidine anesthesia while the control group was given physiological saline with the same dose of the same way infusion. The serum levels of NSE and S-100 B protein levels before the start of CPB and after induction of anesthesia(T1), after the CPB(T2), 6 h After CABG(T3), 24 h After CABG(T4), 48 h After CABG(T5) were measured, and the Sjv O2, Ca-jv O2, Pa O2, CEO2 in T1, T2, T3, T4 were observed. Results NSE, S-100 B protein in T2, T3, T4 of two groups were higher than T1, the differences were statistically significant(P 0.05), and the experimental group were significantly lower than the control group in different time point, the differences were statistically significant(P 0.05). NSE of two groups reached a peak at T3, and S-100 B reached a peak at T2. At T2 and T3, Sjv O2, Pa O2 in experimental group were significantly higher than those of the control group, and Ca-jv O2, CEO2 were significantly lower than those of the control group, the differences between the two groups were statistically significant(P 0.05). Conclusion Dexmedetomidine can reduce the levels of NSE and S-100 B protein in patients with CPB undergoing CABG, and reduce patients' cerebral metabolic rate, alleviate nerve injury caused by CPB.